Ratings by SMBC Nikko Securities (David Dai)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 2/24/2023 | Jounce Therapeutics | JNCE | Downgrade | Neutral (Outperform) |
1.10 (1.88) |
70.91% | Details | |
| 11/3/2022 | CRISPR Therapeutics | CRSP | Maintain | Outperform (N/A) |
|
Details | ||
| 9/29/2022 | Agenus Inc. | AGEN | New Coverage | Outperform (N/A) |
2.04 (6.15) |
201.47% | Details | |
| 7/18/2022 | MacroGenics | MGNX | Downgrade | Neutral (Outperform) |
4.21 (3.31) |
-21.38% | Details | |
| 5/16/2022 | Nkarta Inc. | NKTX | Maintain | Outperform (N/A) |
|
Details | ||
| 5/9/2022 | Xencor, Inc. | XNCR | Maintain | Outperform (N/A) |
|
Details | ||
| 3/31/2022 | Adicet Bio Inc. | ACET | New Coverage | Outperform (N/A) |
18.96 (4.50) |
-76.27% | Details | |
| 3/16/2022 | Inhibrx Inc. | INBX | New Coverage | Outperform (N/A) |
20.19 (89.41) |
342.84% | Details | |
| 3/16/2022 | Jounce Therapeutics | JNCE | New Coverage | Outperform (N/A) |
7.04 (1.88) |
-73.3% | Details | |
| 2/4/2022 | MacroGenics | MGNX | New Coverage | Outperform (N/A) |
11.41 (3.31) |
-70.99% | Details | |
| 1/21/2022 | Xencor, Inc. | XNCR | New Coverage | Outperform (N/A) |
34.97 (22.24) |
-36.4% | Details | |
| 11/18/2021 | Nkarta Inc. | NKTX | New Coverage | Outperform (N/A) |
18.17 (1.80) |
-90.09% | Details | |
| 10/8/2021 | Legand Biotech Corp. | LEGN | New Coverage | Outperform (N/A) |
52.48 (18.04) |
-65.63% | Details |
